US › Healthcare

AN2 Therapeutics Inc (ANTX)

US · Healthcare · Biotechnology

$3.38-6.11%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.2M

EPS

$-0.18

EPS estimate

$-0.24

EPS came in at -0.18 against a street estimate of -0.24 — a beat of 25.0%.

Key statistics

Market cap

$135.1M

Forward P/E

0.0

P/B

2.44

Book value

$2.09

EPS (TTM)

$-1.05

52-week high

$7.19

52-week low

$1.00

50-day MA

$5.45

200-day MA

$3.90

Beta

-0.98

Analyst view

Analysts rate AN2 Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $9.00.

Shareholding

Insiders

15.98%

Institutions

76.88%

Largest institutional holders

Fund	Stake
Vivo Capital, LLC	8.36%
COMMODORE CAPITAL LP	7.77%
Millennium Management LLC	6.14%
BlackRock Inc	4.41%
Spruce Street Capital LP	4.40%
Almitas Capital LLC	3.89%
Vanguard Capital Management, LLC	3.28%
Adage Capital Partners Gp LLC	2.65%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AN2 Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.